Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression

C. L. Arteaga, S. D. Hurd, A. R. Winnier, Mahlon Johnson, B. M. Fendly, J. T. Forbes

Research output: Contribution to journalArticle

307 Citations (Scopus)

Abstract

TGF-β effects on angiogenesis, stroma formation, and immune function suggest its possible involvement in tumor progression. This hypothesis was tested using the 2G7 IgG2b, which neutralizes TGF-β1, -β2, and -β3, and the MDA-231 human breast cancer cell line. Inoculation of these cells in athymic mice decreases mouse spleen natural killer (NK) cell activity. Intraperitoneal injections of 2G7 starting 1 d after intraperitoneal inoculation of tumor cells suppressed intraabdominal tumor and lung metastases, whereas the nonneutralizing anti-TGF-β 12H5 IgG2a had no effect. 2G7 transiently inhibited growth of established MDA-231 subcutaneous tumors. Histologically, both 2G7-treated and control tumors were identical. Intraperitoneal administration of 2G7 resulted in a marked increase in mouse spleen NK cell activity. 2G7 did not inhibit MDA-231 primary tumor or metastases formation, nor did it stimulate NK cell-mediated cytotoxicity in beige NK-deficient nude mice. Finally, serum-free conditioned medium from MDA-231 cells inhibited the NK cell activity of human blood lymphocytes. This inhibition was blocked by the neutralizing anti-TGF-β 2G7 antibody but not by a nonspecific IgG2. These data support a possible role for tumor cell TGF- β in the progression of mammary carcinomas by suppressing host immune surveillance.

Original languageEnglish (US)
Pages (from-to)2569-2576
Number of pages8
JournalJournal of Clinical Investigation
Volume92
Issue number6
DOIs
StatePublished - Jan 1 1993

Fingerprint

Transforming Growth Factors
Natural Killer Cells
Spleen
Breast Neoplasms
Antibodies
Neoplasms
Nude Mice
Neoplasm Metastasis
Serum-Free Culture Media
Conditioned Culture Medium
Intraperitoneal Injections
Human Activities
Immunoglobulin G
Lymphocytes
Cell Line
Lung
Growth

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{4447e63e2c3949f6b4deaa548ce2874e,
title = "Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression",
abstract = "TGF-β effects on angiogenesis, stroma formation, and immune function suggest its possible involvement in tumor progression. This hypothesis was tested using the 2G7 IgG2b, which neutralizes TGF-β1, -β2, and -β3, and the MDA-231 human breast cancer cell line. Inoculation of these cells in athymic mice decreases mouse spleen natural killer (NK) cell activity. Intraperitoneal injections of 2G7 starting 1 d after intraperitoneal inoculation of tumor cells suppressed intraabdominal tumor and lung metastases, whereas the nonneutralizing anti-TGF-β 12H5 IgG2a had no effect. 2G7 transiently inhibited growth of established MDA-231 subcutaneous tumors. Histologically, both 2G7-treated and control tumors were identical. Intraperitoneal administration of 2G7 resulted in a marked increase in mouse spleen NK cell activity. 2G7 did not inhibit MDA-231 primary tumor or metastases formation, nor did it stimulate NK cell-mediated cytotoxicity in beige NK-deficient nude mice. Finally, serum-free conditioned medium from MDA-231 cells inhibited the NK cell activity of human blood lymphocytes. This inhibition was blocked by the neutralizing anti-TGF-β 2G7 antibody but not by a nonspecific IgG2. These data support a possible role for tumor cell TGF- β in the progression of mammary carcinomas by suppressing host immune surveillance.",
author = "Arteaga, {C. L.} and Hurd, {S. D.} and Winnier, {A. R.} and Mahlon Johnson and Fendly, {B. M.} and Forbes, {J. T.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1172/JCI116871",
language = "English (US)",
volume = "92",
pages = "2569--2576",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "6",

}

TY - JOUR

T1 - Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression

AU - Arteaga, C. L.

AU - Hurd, S. D.

AU - Winnier, A. R.

AU - Johnson, Mahlon

AU - Fendly, B. M.

AU - Forbes, J. T.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - TGF-β effects on angiogenesis, stroma formation, and immune function suggest its possible involvement in tumor progression. This hypothesis was tested using the 2G7 IgG2b, which neutralizes TGF-β1, -β2, and -β3, and the MDA-231 human breast cancer cell line. Inoculation of these cells in athymic mice decreases mouse spleen natural killer (NK) cell activity. Intraperitoneal injections of 2G7 starting 1 d after intraperitoneal inoculation of tumor cells suppressed intraabdominal tumor and lung metastases, whereas the nonneutralizing anti-TGF-β 12H5 IgG2a had no effect. 2G7 transiently inhibited growth of established MDA-231 subcutaneous tumors. Histologically, both 2G7-treated and control tumors were identical. Intraperitoneal administration of 2G7 resulted in a marked increase in mouse spleen NK cell activity. 2G7 did not inhibit MDA-231 primary tumor or metastases formation, nor did it stimulate NK cell-mediated cytotoxicity in beige NK-deficient nude mice. Finally, serum-free conditioned medium from MDA-231 cells inhibited the NK cell activity of human blood lymphocytes. This inhibition was blocked by the neutralizing anti-TGF-β 2G7 antibody but not by a nonspecific IgG2. These data support a possible role for tumor cell TGF- β in the progression of mammary carcinomas by suppressing host immune surveillance.

AB - TGF-β effects on angiogenesis, stroma formation, and immune function suggest its possible involvement in tumor progression. This hypothesis was tested using the 2G7 IgG2b, which neutralizes TGF-β1, -β2, and -β3, and the MDA-231 human breast cancer cell line. Inoculation of these cells in athymic mice decreases mouse spleen natural killer (NK) cell activity. Intraperitoneal injections of 2G7 starting 1 d after intraperitoneal inoculation of tumor cells suppressed intraabdominal tumor and lung metastases, whereas the nonneutralizing anti-TGF-β 12H5 IgG2a had no effect. 2G7 transiently inhibited growth of established MDA-231 subcutaneous tumors. Histologically, both 2G7-treated and control tumors were identical. Intraperitoneal administration of 2G7 resulted in a marked increase in mouse spleen NK cell activity. 2G7 did not inhibit MDA-231 primary tumor or metastases formation, nor did it stimulate NK cell-mediated cytotoxicity in beige NK-deficient nude mice. Finally, serum-free conditioned medium from MDA-231 cells inhibited the NK cell activity of human blood lymphocytes. This inhibition was blocked by the neutralizing anti-TGF-β 2G7 antibody but not by a nonspecific IgG2. These data support a possible role for tumor cell TGF- β in the progression of mammary carcinomas by suppressing host immune surveillance.

UR - http://www.scopus.com/inward/record.url?scp=0027137485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027137485&partnerID=8YFLogxK

U2 - 10.1172/JCI116871

DO - 10.1172/JCI116871

M3 - Article

VL - 92

SP - 2569

EP - 2576

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 6

ER -